Bioactive Polymers for Ophthalmic Applications
By covalently bonding bioactive agents to the polymer backbone, the stability and bioavailability of ophthalmic polymers are enhanced, addressing the instability issue in existing polymers and improving the performance of intraocular lenses and other ophthalmic devices.
Patent Information
- Application Number
- JP2024523942
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-22
- Filing Date
- 2022-10-19
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing ophthalmic polymers used in intraocular lenses lack effective bioactive properties due to the bioactive agents not being covalently bonded to the polymer backbone, leading to instability and reduced clinical performance.
Development of bioactive polymers where bioactive agents are covalently bonded to the polymer backbone through conjugation with a moiety to form a bioactive monomer, which undergoes copolymerization with other monomers, creating a stable and bioavailable polymer suitable for ophthalmic applications.
The covalent bonding of bioactive agents to the polymer backbone enhances long-term stability and bioavailability, improving the clinical efficacy of ophthalmic implants and lenses by maintaining bioactive properties.
Smart Images

Figure 2024541217000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application is a nonprovisional patent application and claims priority to U.S. Provisional Patent Application No. 63 / 271,062, filed October 22, 2021, which is incorporated by reference in its entirety. Disclosed herein are novel materials and methods of making and using the same that are particularly useful for ophthalmic applications. More specifically, bioactive polymers, including methods, compositions, and devices for ophthalmic applications, are disclosed. The bioactive polymers disclosed herein are useful for producing relatively soft, optically transparent, foldable, high refractive index materials suitable for use in the manufacture of intraocular lenses, contact lenses, and other ocular implants. [Background technology]
[0002] Since the 1940s, optical devices in the form of intraocular lenses (IOLs) have been utilized as replacements for diseased or damaged natural lenses. In most cases, intraocular lenses are inserted into the eye upon surgical removal of a diseased or damaged natural lens, such as in the case of cataracts. For decades, the preferred material for manufacturing such intraocular lenses has been poly(methyl methacrylate) (PMMA), a hard, glassy polymer. Soft, flexible IOLs have become popular in recent years because they can be compressed, folded, rolled, or otherwise deformed. Such soft IOLs can be deformed before being inserted through an incision in the cornea of the eye. After insertion into the eye, the IOL returns to its original shape before folding due to the memory properties of the soft material. The soft, flexible IOLs mentioned above can be inserted into the eye through incisions of less than 4.0 mm, which is much smaller than the 5.5 to 8.0 mm required to insert a rigid IOL, such as one made of PMMA. Rigid IOLs require larger incisions because they must be inserted into the cornea through an incision that is slightly larger than the diameter of the optic of a less flexible IOL. As a result, larger incisions have sometimes been found to increase the incidence of postoperative complications, such as the development of astigmatism, and therefore rigid IOLs are not widely available in the market.
[0003] Hydrophobic polymers have been used with some success in the manufacture of IOLs over the past decade and have been accepted by the ophthalmic community as having good physical properties and acceptable biocompatibility in the intraocular environment. Polymers are very large molecules made up of many repeating monomer units. They can be natural (e.g., silk and cellulose) or synthetic (e.g., nylon and polyester). Bioactive polymers are polymers that have a biological effect on an organism, tissue, or cell. Synthetic bioactive polymers can be designed for medical applications related to the activity of bioactive agents associated with the polymer matrix. Such applications include ophthalmology. Ophthalmic polymers with bioactive agents have not performed well clinically. The methods used to synthesize these ophthalmic polymers are very complicated, and the bioactive agents are physically placed in the polymer matrix, but are not covalently bonded to the polymer backbone, which greatly reduces the bioavailability of the bioactive agents. Thus, there remains a need for foldable ophthalmic polymers that exhibit bioactive properties. Summary of the Invention
[0004] The present disclosure provides bioactive polymers containing methods, compositions, and devices for ophthalmic applications. In one embodiment, the method may include selecting a bioactive agent, conjugating the bioactive agent to a moiety to produce a bioactive monomer, and then carrying out a copolymerization reaction using the bioactive monomer and one or more other monomers that do not each contain a bioactive agent as reactants. The moiety of the bioactive monomer may react directly with at least one of the other monomers in the copolymerization reaction. In one embodiment, the present disclosure relates to a method for making a bioactive polymer comprising conjugating a bioactive agent to a moiety to produce a bioactive monomer, and carrying out a copolymerization reaction using the bioactive monomer and one or more other monomers, each of which does not contain a bioactive agent, as reactants, wherein the moiety of the bioactive monomer reacts directly with at least one of the other monomers in the copolymerization reaction. In one embodiment, the disclosure relates to a method for making a bioactive polymer comprising conjugating a bioactive agent to a first alkenyl moiety to produce a bioactive monomer, and performing an alkenyl-based copolymerization reaction using as reactants at least the bioactive monomer and one or more other monomers, each of which contains an alkenyl moiety and does not contain a bioactive agent, to produce the bioactive polymer. In one embodiment, the bioactive agent is selected from the group consisting of at least one of a protein, a protein fragment, a peptide, a polysaccharide, a polypeptide of at least 50 amino acids, a proteoglycan, an extracellular matrix protein, an antimicrobial agent, and a therapeutic agent.
[0005] In one embodiment, at least one of the one or more other monomers is an acrylic compound, which in one embodiment is independently acrylic acid or an α / β-substituted acrylic acid, an acrylic acid ester or an α / β-substituted acrylic acid ester, or an acrylamide or an α / β-substituted acrylamide. In one embodiment, at least one monomer of the one or more other monomers comprises a methacrylate compound, a methyl methacrylate compound, a hydroxyethyl acrylate compound, or a hydroxyethyl methacrylate compound. In one embodiment, the one or more other monomers comprises a hydrophilic monomer and a hydrophobic monomer. In one embodiment, the hydrophilic monomer has a hydroxyalkyl group bonded directly to the oxygen atom of the ester functional group. In one embodiment, the hydrophobic monomer has an alkyl group bonded directly to the oxygen atom of the ester functional group. In one embodiment, the bioactive polymer has a refractive index of 1.4 to 1.6 or 1.45 to 1.55. In one embodiment, the method further comprises hydrating the bioactive polymer, wherein the equilibrium water content of the hydrated bioactive polymer is between 10-50% or between 15-40%. In one embodiment, the present disclosure relates to bioactive polymers produced by the methods disclosed herein.
[0006] In one embodiment, the present disclosure relates to a bioactive polymer comprising a bioactive monomeric component that comprises a bioactive agent and one or more other monomeric components that each do not comprise a bioactive agent, the bioactive polymer comprising a backbone that covalently bonds the bioactive monomeric component to each of the one or more other monomeric components, in one embodiment, each unit of the bioactive monomeric component contributes at least two carbon atoms to the backbone, and each unit of each monomeric component of the one or more other monomeric components contributes exactly two carbon atoms to the backbone. In one embodiment, the present disclosure relates to a bioactive polymer comprising a bioactive monomer component that includes a bioactive agent and one or more hydrophilic monomers that do not each include a bioactive agent, the bioactive polymer comprising a backbone that covalently bonds the bioactive monomer component to each of the one or more hydrophilic monomer components, in one embodiment, each unit of the bioactive monomer component contributes at least two carbon atoms to the backbone, and each unit of each hydrophilic monomer component of the one or more other hydrophilic monomer components contributes exactly two carbon atoms to the backbone. In one embodiment, the present disclosure relates to a bioactive polymer comprising a bioactive monomeric component comprising a bioactive agent and a copolymer comprising at least two hydrophilic monomers each not comprising a bioactive agent, the bioactive polymer comprising a backbone covalently linking the bioactive monomeric component to at least one of the two or more hydrophilic monomers, in one embodiment, each unit of the bioactive monomeric component donates at least two carbon atoms to the backbone, and at least one of the two hydrophilic monomers donates exactly two carbon atoms to the backbone. In one embodiment, the present disclosure relates to a bioactive polymer comprising a bioactive monomer component comprising a bioactive agent and a copolymer comprising at least one hydrophilic monomer and at least one hydrophobic monomer, each of which does not comprise a bioactive agent, the bioactive polymer comprising a backbone covalently linking the bioactive monomer component to at least one of the hydrophobic and hydrophilic monomers, in one embodiment, each unit of the bioactive monomer component contributes at least two carbon atoms to the backbone, and at least one of the hydrophilic and hydrophobic monomers contributes exactly two carbon atoms to the backbone. In one embodiment, units of a biologically active monomeric component are interspersed along the backbone with units of one or more other monomeric components. In one embodiment, the one or more other monomeric components form a majority of the bioactive copolymer, hi one embodiment, the one or more other monomeric components form at least 80, 90, 95, or 98% of the bioactive polymer by mass or number of units. In one embodiment, the bioactive polymer comprises an acrylic polymer. In one embodiment, the one or more other monomers comprise a hydrophilic monomer. In another embodiment, the one or more other monomers comprise a hydrophobic monomer. In yet another embodiment, the one or more other monomers form a copolymer comprising a hydrophilic monomer and a hydrophobic monomer. In another embodiment, the one or more other monomers may comprise an ultraviolet light blocking monomer, and / or a crosslinking monomer, and / or a blue light blocking monomer. [Brief description of the drawings]
[0007] [Figure 1]FIG. 1 is a non-limiting representative diagram showing the reaction of a bioactive monomer having a bioactive agent with a monomer that does not contain a bioactive agent. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0008] definition All references to the Periodic Table of the Elements refer to the Periodic Table of the Elements, published and copyrighted by CRC Press, Inc. in 1990. Also, any reference to one or more groups shall refer to one or more groups reflected in the Periodic Table of the Elements using the IUPAC nomenclature for numbering the groups. Unless stated to the contrary, implied from the context, or customary in the art, all parts and percentages are by weight and all test methods are as of the filing date of this disclosure. For purposes of U.S. patent practice, the contents of any referenced patents, patent applications, or publications are incorporated by reference in their entirety (or the equivalent U.S. version thereof is so incorporated by reference), particularly with respect to disclosure of synthetic techniques, product and process designs, polymers, catalysts, definitions (to the extent not inconsistent with definitions specifically set forth in this disclosure), and general knowledge in the art.
[0009] Numerical ranges in this disclosure are approximate and may include values outside the range unless otherwise indicated. Numerical ranges include all values, including the lower and upper limits, by 1 unit, if there is a separation of at least 2 units between any lower limit and any upper limit. As an example, if a compositional, physical, or other property, such as molecular weight, viscosity, melt index, etc., is 100 to 1,000, all individual values such as 100, 101, 102, etc., and subranges such as 100 to 144, 155 to 170, 197 to 200, etc., are intended to be explicitly recited. For ranges containing values less than 1, or containing fractional numbers greater than 1 (e.g., 1.1, 1.5, etc.), one unit is considered to be 0.0001, 0.001, 0.01, or 0.1, as appropriate. For ranges containing single digit numbers less than 10 (e.g., 1 to 5), one unit is typically considered to be 0.1. These are merely examples of what is specifically intended, and all possible combinations of numerical values between the lowest and highest values recited are considered to be expressly set forth in this disclosure. Numerical ranges are provided within this disclosure, particularly for the weight percent of components in the compositions disclosed herein. The term "about" as used herein in conjunction with a numerical range modifies that range by extending the upper and lower limits of the numerical values set forth. In one embodiment, the term "about" is used herein to modify a numerical value above and below the set forth value by a variance of 10%. Thus, about 50% includes a range of 45-55%.
[0010] As used herein, "bioactive agent" refers to a substance capable of exerting a biological effect in vitro and / or in vivo. Bioactive agents may be neutral, positively or negatively charged. Examples of suitable bioactive agents include diagnostic agents, pharmaceuticals, drugs, synthetic organic molecules, proteins, peptides, vitamins, steroids, steroid analogs, and genetic material including nucleosides, nucleotides, and polynucleotides. In one embodiment, the bioactive agent comprises a pharmaceutical and / or a drug. When used in reference to a compound, unless otherwise specified, the singular form includes all isomers and vice versa (e.g., "hexane" includes all isomers of hexane individually or collectively). The terms "compound" and "complex" are used interchangeably and refer to organic, inorganic, and organometallic compounds. The term "atom" refers to the smallest building block of an element, regardless of its ionic state, i.e., whether it carries an electric or partial charge or is bonded to another atom.
[0011] As used herein, the terms "comprising," "including," "having," and similar terms are not intended to exclude the presence of any additional components, steps, or procedures, whether or not they are specifically disclosed. For the avoidance of doubt, all processes claimed by use of the term "comprising" may include one or more additional steps, parts or components of apparatus, and / or materials, unless stated to the contrary. In contrast, the term "consisting essentially of" excludes from the scope of any succeeding description any other components, steps, or procedures, except those that are not essential to operability. The term "consisting of" excludes any components, steps, or procedures not specifically delineated or listed. The term "or" refers to the listed members individually as well as in any combination, unless otherwise stated. As used herein, the term "composition" and similar terms refer to a mixture or blend of two or more components. As used herein, the term "copolymer" refers to polymers prepared from two different monomers, and to polymers prepared from three or more different monomers, such as terpolymers, tetrapolymers, etc. As used herein, the term diopter (D) refers to the reciprocal of the focal length of a lens in meters. For example, a 10D lens focuses parallel light rays to a focal point at (1 / 10) meters. After surgically removing the patient's natural crystalline lens, the surgeon will usually calculate the desired diopter (D) to correct the patient's preoperative refractive error based on his or her own personal preference and according to a formula to select an IOL for the patient. For example, if a patient with -10D myopia undergoes cataract surgery and IOL implantation, the patient can see far enough without glasses. This is because the surgeon considered the patient's -10D myopia when selecting the IOL.
[0012] As used herein, "intraocular lens" refers to a polymeric phakic or aphakic (also referred to in the art as pseudophakic) vision correction device that may be inserted into a patient's eye. Phakic lenses are used to correct refractive errors such as myopia (near vision), hyperopia (far vision), and astigmatism (blurred vision due to lack of focus on the retina due to distortion of the cornea or sometimes the lens). The natural lens remains in place when a phakic lens is inserted, but is removed when a pseudophakic lens is inserted. Aphakic or pseudophakic lenses are inserted into the eye after the natural lens has been removed due to disease (often a cataract that clouds the natural lens). Both types of lenses are inserted into the anterior chamber, in front of the iris, or into the posterior chamber, behind the iris and in front of the natural lens, or in the area where the natural lens was before it was removed. Intraocular lenses can be "hard", i.e., relatively inflexible, or "soft", i.e., relatively flexible but not foldable, although the presently preferred lenses for purposes of the present invention are foldable acrylic polymer lenses. A foldable lens is a lens that is flexible enough that it can be folded into a configuration small enough that it can be inserted into the eye through a much smaller incision than is required for hard or soft lenses. That is, while hard and soft lenses may require an incision of 6 mm or more, a foldable lens typically requires only an incision of 3 mm or less. U.S. Patent No. 7,789,509 to Mentak, U.S. Patent No. 6,281,319 to Mentak, U.S. Patent No. 6,635,731 to Mentak, U.S. Patent No. 6,635,732 to Mentak, and U.S. Patent No. 7,083,645 to Mentak, U.S. Patent No. 7,789,509 to Mentak et al., and U.S. Patent No. 7,399,811 also to Mentak et al. are all incorporated by reference in their entireties herein.
[0013] As used herein, "optical component," "optical assembly," or "optical subassembly" shall mean a portion of, or a complete, ophthalmic device, assembly, or subassembly. Non-limiting examples of optical components include lens bodies, optics, haptics, and IOL components. As used herein, "optical polymer" refers to a polymer suitable for insertion into a patient's eye and capable of addressing ophthalmic conditions of the eye lens, including, but not limited to, myopia, hyperopia, astigmatism, and cataracts. Generally, such polymers are biocompatible, i.e., do not cause inflammatory, immunogenic, or toxic conditions upon insertion, form colorless and transparent (unless intentionally colored for a particular application), film-like membranes, and have a refractive index greater than about 1.4, preferably greater than about 1.5, and currently most preferably greater than about 1.55. As used herein, "pharmaceutical product" or "drug" refers to any therapeutic or prophylactic agent that may be used in the treatment (including prevention, diagnosis, mitigation, or cure) of a disease, affliction, disorder, or injury in a patient. Therapeutically useful peptides, polypeptides, and polynucleotides are included within the meaning of the term pharmaceutical product or drug. As used herein, the term "polymer" (and similar terms) is a macromolecular compound prepared by reacting (i.e., polymerizing) monomers of the same type (homopolymer) or different types (copolymer). "Polymer" includes homopolymers and copolymers. As used herein, the refractive index or index of refraction of a material is a dimensionless number that describes the propagation of light in a medium, where c is defined as the speed of light in a vacuum and v is the phase velocity of light in the medium. For example, the refractive index of water is 1.333, meaning that light travels 1.333 times faster in a vacuum than in water.
[0014] The apparatus and method disclosed herein will be described in more detail below with reference to the accompanying drawings showing embodiments of the present disclosure. However, the apparatus and method disclosed herein can be embodied in many different forms and should not be construed as being limited to the embodiments described herein. Rather, the provision of these embodiments will ensure that the disclosure is thorough and complete, and will fully convey the scope of the present invention to those skilled in the art. Those skilled in the art will appreciate that the set of features and / or functions may be readily varied in the context of independent sights, forward or rear mounted clip-on sights, and other arrangements of optical sights deployed in the field. Additionally, those skilled in the art will appreciate that various combinations of features and functions may be incorporated into add-on modules for retrofitting any type of existing fixed or variable sight. When an element or layer is referred to as being "on", "connected to", or "coupled to" another element or layer, it will be understood that it can be directly on, connected to, or coupled to the other element or layer. Alternatively, intervening elements or layers may be present. In contrast, when an element is referred to as being "directly on", "directly connected to", or "directly coupled to" another element or layer, there are no intervening elements or layers present.
[0015] Like numbers refer to like elements throughout. As used herein, the term "and / or" includes any and all combinations of one or more of the associated listed items. In this specification, terms such as first, second, etc. may be used to describe various elements, components, regions, and / or portions, but it will be understood that these elements, components, regions, and / or portions should not be limited by these terms. These terms are only used to distinguish one element, component, region, or portion from another element, component, region, or portion. Thus, a first element, component, region, or portion described below can be referred to as a second element, component, region, or portion without departing from this disclosure. For ease of description, spatially relative terms such as "below," "below," "lower than," "above," and "above" may be used herein to describe the relationship of one element or feature shown in the figures to another element(s) or feature(s). It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted. For example, if the device in the figures were turned over, an element described as "below" or "below" the other element or feature would then be oriented "above" the other element or feature. Thus, the exemplary term "below" can encompass both an orientation of above and below. The device may be in other orientations (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein would be interpreted accordingly.
[0016] Bioactive Polymers In one embodiment, the present disclosure provides bioactive polymer containing methods, compositions, and devices for ophthalmic applications. In bioactive polymers, bioactive agents are covalently attached to the polymer backbone, resulting in improved long-term stability and bioavailability. These bioactive polymers can be used in the manufacture of ophthalmic implants (e.g., intraocular lenses), contact lenses, and other devices. In one embodiment, the present disclosure relates to a bioactive polymer comprising a bioactive monomer component comprising a bioactive agent and one or more other monomer components each not comprising a bioactive agent. In one embodiment, the monomer component is a hydrophilic monomer. In yet another embodiment, the monomer component is a hydrophobic monomer. In one embodiment, the one or more other components for a copolymer. In one embodiment, the copolymer comprises at least two hydrophilic monomers. In another embodiment, the copolymer comprises at least two hydrophobic monomers. In yet another embodiment, the copolymer comprises at least one hydrophilic monomer and at least one hydrophobic monomer.
[0017] In another embodiment, the present disclosure relates to a bioactive polymer comprising a bioactive monomeric component that comprises a bioactive agent and one or more other monomeric components that each do not comprise a bioactive agent, the bioactive polymer comprising a backbone that covalently bonds the bioactive monomeric component to each of the one or more other monomeric components, each unit of the bioactive monomeric component donating at least two carbon atoms to the backbone, and each unit of each monomeric component of the one or more other monomeric components donating exactly two carbon atoms to the backbone. In another embodiment, the present disclosure relates to a bioactive polymer comprising a bioactive monomeric component that comprises a bioactive agent and one or more other monomeric components that each do not comprise a bioactive agent, the bioactive polymer comprising a backbone that covalently bonds the bioactive monomeric component to at least one of the one or more other monomeric components, each unit of the bioactive monomeric component donating at least two carbon atoms to the backbone, and at least one of the one or more other monomeric components donating exactly two carbon atoms to the backbone. In another embodiment, the present disclosure relates to a bioactive polymer comprising a bioactive monomeric component that comprises a bioactive agent and a copolymer that comprises at least two other monomeric components that do not each comprise a bioactive agent, wherein the bioactive polymer comprises a backbone that covalently bonds the bioactive monomeric component to at least one of the monomeric components of the copolymer, each unit of the bioactive monomeric component donating at least two carbon atoms to the backbone, and at least one monomeric component of the copolymer donating exactly two carbon atoms to the backbone. In another embodiment, the present disclosure relates to a bioactive polymer comprising a bioactive monomer component comprising a bioactive agent and one or more hydrophilic monomers, wherein the bioactive agent is covalently bonded to the one or more hydrophilic monomers. In another embodiment, the present disclosure relates to a bioactive polymer comprising a bioactive monomer component comprising a bioactive agent, one or more hydrophilic monomers, and one or more hydrophobic monomers, wherein the bioactive agent is covalently bonded to at least one of the hydrophilic and hydrophobic monomers. In another embodiment, the present disclosure relates to a bioactive polymer comprising a bioactive monomer component comprising a bioactive agent, one or more hydrophilic monomers, and one or more hydrophobic monomers, wherein the bioactive agent is covalently bonded to the one or more hydrophilic monomers and the one or more hydrophobic monomers.
[0018] In another embodiment, the present disclosure relates to a bioactive polymer comprising a bioactive monomer component comprising a bioactive agent, from about 0.001 to about 0.1% by weight of the polymer, one or more hydrophilic monomers, from about 45 to about 55% by weight of the polymer, and one or more hydrophobic monomers, from about 40 to about 50% by weight of the polymer. In another embodiment, the present disclosure relates to a bioactive polymer comprising a bioactive monomer component comprising a bioactive agent, from about 0.001 to about 0.1% by weight of the polymer, one or more hydrophilic monomers, from about 30 to 45% by weight of the polymer, and one or more hydrophobic monomers, from about 50 to 65% by weight of the polymer. In another embodiment, the bioactive polymer may include a crosslinker, hi yet another embodiment, the bioactive polymer may include an ultraviolet light absorbing agent.
[0019] Bioactive Agents We have surprisingly discovered that it is important that the bioactive agent is functionalized with groups that allow for simultaneous polymerization with the bulk of the material. We have found that the methods disclosed herein can improve the affinity of the bioactive agent to the polymer matrix, thereby reducing or eliminating phase separation, improving solubility in the comonomer solution, and / or facilitating covalent copolymerization. This novel approach preserves the specific biological activity of the bioactive agent and provides long-term stability and optical transparency. An important aspect of the present disclosure is that functionalized bioactive agents can be added to existing polymer formulations to impart bioactivity without affecting their physical properties, resulting in improved biocompatibility. Without being bound to a particular theory, a representative, non-limiting depiction of a method for making a bioactive polymer is shown in Figure 1. Methacrylated collagen is shown as the bioactive monomer with collagen as the bioactive agent. Hydroxyethyl methacrylate (HMEA) is shown as the monomer, in this case the hydrophilic monomer. HEMA and the methyacrylated collagen are mixed with a crosslinker (EDGMA). A free radical initiator (e.g., AIBN) is used to initiate the polymerization. In one embodiment, the bioactive agent can be a polypeptide (e.g., a protein or protein fragment), a peptide, a polysaccharide, a proteoglycan, an antimicrobial agent, a therapeutic agent, etc. In some examples, the bioactive agent can include an extracellular matrix protein, or a sequence of at least 5, 10, 25, 50, or 100 amino acids of an extracellular matrix protein. In some examples, the extracellular matrix protein can be collagen, elastin, keratin, vimentin, fibronectin, or laminin. In another embodiment, the bioactive agent can be gelation, heparin, or hyaluronic acid.
[0020] In one embodiment, bioactive agents useful in the methods and compositions disclosed herein are therapeutic substances with desirable therapeutic properties, including, but not limited to, thrombin inhibitors, antithrombotic agents, thrombolytic agents, fibrinolytic agents, vasospasm inhibitors, calcium channel blockers, vasodilators, antihypertensive agents, antibacterial agents, antibiotics, inhibitors of surface glycoprotein receptors, antiplatelet agents, antimitotic agents, microtubule inhibitors, antisecretory agents, actin inhibitors, remodeling inhibitors, antisense nucleotides, antimetabolites, antiproliferative agents (including angiogenesis inhibitors), anticancer chemotherapeutic agents, anti-inflammatory steroids or nonsteroidal anti-inflammatory agents, immunosuppressants, growth hormone antagonists, growth factors, dopamine agonists, radiotherapeutic agents, peptides, proteins, enzymes, extracellular matrix components, ACE inhibitors, free radical scavengers, chelators, antioxidants, antipolymerases, antiviral agents, photodynamic therapeutic agents, and gene therapeutic agents. In another embodiment, a wide variety of bioactive agents are available that may be suitable for use in the compositions and methods disclosed herein. The particular bioactive agent used may vary and will depend, for example, on the disease state, the therapeutic effect being sought, the particular patient involved, etc. Bioactive agents that may be used in the compositions and methods disclosed herein include diagnostic agents, genetic material, peptides, beta agonists, antiasthmatics, steroids, cholinergics, anticholinergics, 5-lipoxygenase inhibitors, leukotriene inhibitors, antineoplastics, antibiotics, antineoplastics, radiosensitizers, thrombolytics, antihistamines, anticoagulants, anti-inflammatory agents, hormones, growth factors, angiogenic factors, and mitotic inhibitors. Exemplary genetic material includes, for example, nucleic acids, RNA, DNA, recombinant RNA, recombinant DNA, antisense RNA, antisense DNA, hammerhead RNA, hammerhead ribozymes, antigene nucleic acids, ribooligonucleotides, deoxyribooligonucleotides, antisense ribooligonucleotides, and antisense deoxyribooligonucleotides.
[0021] In one embodiment, the bioactive agent is an antineoplastic agent for treating cancer. A particularly preferred antineoplastic agent is taxol (Westwood Squibb). In another embodiment, the bioactive agent is a thrombolytic agent for treating thrombosis, including thrombosis of cardiac tissue. Exemplary thrombolytic agents include, for example, streptokinase, urokinase, tissue plasminogen activator, alteplase, anistreplase, reteplase, and saruplase, with streptokinase being preferred. In another embodiment, the bioactive monomer component comprising a bioactive agent is about 0.001 to about 0.1% by weight of the composition. In another embodiment, the bioactive monomer component comprising a bioactive agent is about 0.002% by weight of the composition. In yet another embodiment, the bioactive monomer component comprising a bioactive agent is about 0.001 to about 0.005% by weight of the composition.
[0022] Hydrophilic Monomers Suitable hydrophilic monomers (i.e., monomers whose homopolymers are hydrophilic according to the present invention) include, but are not limited to, 2-hydroxyethyl acrylate, 2-hydroxyethyl methacrylate, acrylamide, N-omithine acrylamide, N-(2-hydroxypropyl)acrylamide, polyethylene glycol acrylate, polyethylene glycol methacrylate, N-vinylpyrrolidone, N-phenylacrylamide, dimethylaminopropyl methacrylamide, acrylic acid, benzyl methacrylamide, 4-hydroxybutyl methacrylate, glycerol monomethacrylate, glycerol monoacrylate, 2-sulfoethyl methacrylate, phenoxyethyl acrylate, phenoxyethyl methacrylate, 2-(2-ethoxyethoxy)ethyl acrylate, 2-(2-ethoxyethoxy)ethyl methacrylate, furfuryl acrylate, furfuryl methacrylate, and methylthioethyl acrylamide. In another embodiment, the one or more hydrophilic monomers comprise from about 30 to about 65% by weight of the copolymer, or from about 35 to about 65% by weight of the copolymer, or from about 40 to about 65% by weight of the copolymer, or from about 45 to about 65% by weight of the copolymer, or from about 50 to about 65% by weight of the copolymer, or from about 55 to about 65% by weight of the copolymer, or from about 60 to about 65% by weight. In yet other embodiments, the one or more hydrophilic monomers comprise from about 35 to about 55 weight percent of the copolymer, or from about 40 to about 55 weight percent of the copolymer, or from about 45 to about 55 weight percent of the copolymer, or from about 50 to about 55 weight percent of the copolymer. In yet other embodiments, the one or more hydrophilic monomers comprise from about 90 to about 97% by weight of the copolymer, or from about 92 to about 97% by weight of the copolymer, or from about 94 to about 97% by weight of the copolymer, or from about 95 to about 97% by weight of the copolymer.
[0023] Hydrophobic Monomers Suitable hydrophobic monomers (i.e., monomers whose homopolymers are hydrophobic in accordance with the present invention) include, but are not limited to, lauryl methacrylate, lauryl acrylate, 2-ethylhexyl acrylate, 2-ethylhexyl methacrylate, n-decyl acrylate, n-decyl methacrylate, hexyl acrylate, hexyl methacrylate, stearyl acrylate, stearyl methacrylate, isodecyl acrylate, isodecyl methacrylate, isobornyl acrylate, isobornyl methacrylate, vinyl laurate, vinyl stearate, 1-hexadecyl acrylate, 1-hexadecyl methacrylate, n-myristyl acrylate, n-myristyl methacrylate, n-dodecyl methacrylamide, butyl acrylate, n-butyl methacrylate, isooctyl acrylate, isotridecyl acrylate, isooctyl methacrylate, isotridecyl methacrylate. In another embodiment, the one or more hydrophobic monomers comprise from about 40 to about 70% by weight of the copolymer, or from about 45 to about 70% by weight of the copolymer, or from about 45 to about 70% by weight of the copolymer, or from about 50 to about 70% by weight of the copolymer, or from about 55 to about 70% by weight of the copolymer, or from about 60 to about 70% by weight of the copolymer, or from about 65 to about 70% by weight of the copolymer. In yet other embodiments, the one or more hydrophobic monomers comprise from about 45 to about 65 weight percent of the copolymer, or from about 50 to about 65 weight percent of the copolymer, or from about 55 to about 65 weight percent of the copolymer, or from about 60 to about 65 weight percent of the copolymer.
[0024] Crosslinking Agent Suitable crosslinking agents include, but are not limited to, ethylene glycol dimethacrylate (EGDMDA), diethylene glycol dimethacrylate, triethylene glycol dimethacrylate, and poly(ethylene glycol) dimethacrylate, with ethylene glycol dimethacrylate being preferred. Suitable initiators include, but are not limited to, azobis(isobutyronitrile), 2,2'-azobis(2,4-dimethylvaleronitrile), 2,2'-azobis(methylbutyronitrile), 1,1'-azobis(cyanocyclohexane), di-t-butyl peroxide, dicumyl peroxide, t-butylcumyl peroxide, 2,5-dimethyl-2,5-bis(2-ethylhexanoylperoxy)hexane, t-butylperoxyneodecanoate ... canote), t-butyl peroxy 2-ethylhexanoate, di(4-t-butylcyclohexyl) peroxydicarbonate, t-butyl peroxypivalate, decanoyl peroxide, lauroyl peroxide, benzoyl peroxide, 2,4-pentanedione peroxide, di(n-propyl) peroxydicarbonate, t-amyl peroxyneodecanoate, and t-butyl peroxyacetate, with 2,2'-azobis(isobutyronitrile) being preferred. In one embodiment, the crosslinker may be present in from about 0.1 to about 10% by weight of the composition, or from about 0.3 to about 10% by weight of the composition, or from about 0.5 to about 10% by weight of the composition, or from about 1 to about 10% by weight of the composition, or from about 2 to about 10% by weight of the composition, or from about 3 to about 10% by weight of the composition, or from about 4 to about 10% by weight of the composition, or from about 5 to about 10% by weight of the composition, or from about 6 to about 10% by weight of the composition. In one embodiment, the crosslinker may be present in about 1 to about 5% by weight of the composition, or about 2 to about 5% by weight of the composition, or about 3 to about 5% by weight of the composition, or about 4 to about 5% by weight of the composition.
[0025] UV absorbers Suitable UV absorbers include, for example, β-(4-benzotriazoyl-3-hydroxyphenoxy)ethyl acrylate, 4-(2-acryloxyethoxy)-2-hydroxybenzophenone, 4-methacryloxy-2-hydroxybenzophenone, 2-(2'-methacryloxy-5'-methylphenyl)benzotriazole, 2-(2'-hydroxy-5'-methacryloxyethylphenyl)-2H-benzotriazole, 2-[3'-tert-butyl-T-hydroxy-5'-(3''-methacryloyloxypropyl)phenyl]-5-chloro-benzotriazole, 2-(3'-tert-butyl-5'[3''-methacryloyloxypropyl)phenyl]-5-chloro-benzotriazole, 2-(3'-tert-butyl-5'[3''-methacryloyloxypropyl)phenyl)-5-chloro-benzotriazole,
[0036] Examples of the ultraviolet absorber include, but are not limited to, 2-(3'-allyl-2'-hydroxy-5'-methylphenyl)benzo-triazole, 2-[3'-tert-butyl-2'-hydroxy-5'-(3''-methacryloyloxypropoxy)phenyl]-5-methoxybenzotriazole, and 2-[3'-tert-butyl-2'-hydroxy-5'-(3''-methacryloyloxypropoxy)phenyl]-5-chlorobenzotriazole, with β-(4-benzotriazole-3-hydroxyphenoxy)ethyl acrylate being the preferred ultraviolet absorber. UV absorbers can be optionally added to the copolymer composition. A new preferred UV / blue light absorber, namely vinyl anthracene, can be added to the copolymer composition. Conventional UV absorbers such as vinyl benzophenone or vinyl benzotriazole can also be used. In another embodiment, the UV absorber may be present in about 0.1 to about 5% by weight of the composition, or about 0.2 to about 5% by weight of the composition, or about 0.4 to about 5% by weight of the composition, or about 0.6 to about 5% by weight of the composition, or about 0.8 to about 5% by weight of the composition, or about 1 to about 5% by weight of the composition, or about 1.5 to about 5% by weight of the composition, or about 2 to about 5% by weight of the composition, or about 3 to about 5% by weight of the composition, or about 4 to about 5% by weight of the composition.
[0026] Monomer Dyes Monomeric dyes copolymerizable with the hydrophobic and hydrophilic monomers may optionally be added to the copolymer to attenuate certain wavelengths of light. Such dyes include, but are not limited to, those containing vinyl groups and can absorb violet, blue, red, and green light in the range of 400-700 nm. Examples of such monomeric dyes include, but are not limited to: Disperse Red 13 Acrylate Disperse Orange 3 Acrylamide Disperse Orange 3 Methacrylamide Disperse Red 1 Methacrylate Disperse Red 1 Acrylate Disperse Red 13 Methacrylate Disperse Yellow 7 Acrylate Disperse Yellow 7 Methacrylate Ethyl trans-α-cyano-3-indole acrylate [(S)-(-)-1-(4-nitrophenyl)-2-pyrrolidinemethyl]acrylate
[0027] Manufacturing method The present disclosure provides methods for making bioactive polymers. These methods may include: (1) selecting a bioactive agent, (2) conjugating the bioactive agent to a moiety to produce a bioactive monomer, and (3) performing a copolymerization reaction using as reactants the bioactive monomer and one or more other monomers each of which does not contain a bioactive agent. The moiety of the bioactive monomer may react directly with at least one of the other monomers in the copolymerization reaction. The method may also include (1) selecting a bioactive agent, (2) conjugating the bioactive agent to a first alkenyl moiety to form a bioactive monomer, and (3) performing an alkenyl-based copolymerization reaction to form a bioactive polymer. The reactants may include at least the bioactive monomer and one or more other monomers, each of which includes an alkenyl moiety and does not include a bioactive agent. A bioactive polymer may include (1) a bioactive monomeric component that includes a bioactive agent, and (2) one or more other monomeric components, each of which does not include a bioactive agent. A bioactive polymer may include a backbone that covalently bonds the bioactive monomeric component to each of the one or more other monomeric components. Each unit of the bioactive monomeric component may donate at least two carbon atoms to the backbone, and each unit of each monomeric component of the one or more other monomeric components may donate at least two carbon atoms (e.g., exactly two carbon atoms) to the backbone.
[0028] The compositions and methods disclosed herein can be further illustrated by the following paragraphs. A1. A method for producing a bioactive polymer, comprising: selecting a bioactive agent; conjugating a bioactive agent to the moiety to form a bioactive monomer; and Conducting a copolymerization reaction using as reactants a bioactive monomer and one or more other monomers each not containing a bioactive agent, wherein a moiety of the bioactive monomer reacts directly with at least one of the other monomers in the copolymerization reaction. The method includes: A2. The method of paragraph A1, producing an acrylic polymer or a silicone polymer. A3. The method of any one of A1 to A2, producing a matrix for an ophthalmic lens. A4. The method of any one of A3, wherein the matrix is foldable without breaking, tearing, or shearing. A5. The method of any one of paragraphs A1-A4, wherein the bioactive agent comprises a protein, a protein fragment, a polypeptide of at least 50 amino acids, a peptide of 2-49 amino acids, a proteoglycan, a polysaccharide, an antimicrobial agent, and / or a therapeutic agent. A6. The method of paragraph A5, wherein the bioactive agent comprises an extracellular matrix protein, or a sequence of at least 5, 10, 25, 50, or 100 amino acids of an extracellular matrix protein. A7. The method of A6, wherein the extracellular matrix protein is collagen, elastin, keratin, vimentin, fibronectin, or laminin.
[0029] B1. A method for producing a bioactive polymer, comprising: selecting a bioactive agent; conjugating a bioactive agent to the first alkenyl moiety to form a bioactive monomer; and conducting an alkenyl-based copolymerization reaction using as reactants at least the bioactive monomer and one or more other monomers, each of which contains an alkenyl moiety and does not contain a bioactive agent, to produce a bioactive polymer; The method includes: B2. The method of paragraph B1, wherein the bioactive agent comprises at least one of a protein, a peptide, a polysaccharide, an antimicrobial agent, and a therapeutic agent. B3. The method of paragraph B1 or B2, wherein at least one of the one or more other monomers is an acrylic compound. B4. The method of paragraph B3, wherein the acrylic compounds are independently acrylic acid or α / β substituted acrylic acid, an acrylic acid ester or α / β substituted acrylic acid ester, or an acrylamide or α / β substituted acrylamide. B5. The method of any one of paragraphs B1-B4, wherein at least one of the one or more other monomers comprises a methacrylate compound, a methyl methacrylate compound, a hydroxyethyl acrylate compound, or a hydroxyethyl methacrylate compound. B6. The method of any one of paragraphs B1-B5, wherein the one or more other monomers include a hydrophilic monomer and a hydrophobic monomer. B7. The method of paragraph B6, wherein the hydrophilic monomer has a hydroxyalkyl group attached directly to the oxygen atom of the ester functional group. B8. The method of any one of paragraphs B6 to B7, wherein the hydrophobic monomer has an alkyl group bonded directly to the oxygen atom of the ester functional group. B9. The method of any one of paragraphs B1-B8, wherein the bioactive polymer comprises an acrylic polymer. B10. The method of any one of paragraphs B1-B9, wherein conjugating comprises conjugating the bioactive agent to the first alkenyl moiety via at least one bond selected from an amide, amino, ester, ether, carbonyl, organic anhydride, and organic sulfur bond. B11. The method of any one of paragraphs B1-B10, wherein the first alkenyl moiety is provided by an acryl compound. B12. The method according to B11, wherein the acrylic compound is acrylic acid or an α / β substituted acrylic acid. B13. The method of paragraph B12, wherein the acrylic compound is methacrylic acid. B14. The method of any one of paragraphs B1-B13, wherein conjugating comprises reacting an amine of the bioactive agent with a carboxyl group of the first alkenyl moiety. B15. The method of B14, wherein conjugating comprises activating the carboxyl group with 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide (EDC) and / or N-hydroxysuccinimide (NHS). B16. The method of paragraph B14, wherein the amine is provided by one or more lysine residues of the bioactive agent. B17. The method of any one of paragraphs B1-B16, wherein the one or more other monomers comprises a crosslinking monomer having at least two alkenyl groups per molecule. B18. The method of paragraph B17, wherein the cross-linking monomer is ethylene glycol dimethacrylate. B19. The method of any one of paragraphs B1-B18, wherein the one or more other monomers comprises an ultraviolet light blocking monomer. B20. The method of B19, wherein the UV blocking monomer is vinylbenzotriazole or vinylbenzophenone. B21. The method of any one of paragraphs B1-B20, wherein the one or more other monomers comprises a blue-light blocking chromophore. B22. The method of any one of paragraphs B1-B21, wherein the blue light blocking chromophore comprises vinyl anthracene and / or Disperse Orange 3 methacrylamide (2-methyl-N-[4-[(4-nitrophenyl)diazenyl]phenyl]prop-2-enamide). B23. The method of any one of paragraphs B1-B22, carried out in a reaction mixture that includes a free radical initiator. B24. The method according to paragraph B1, wherein the bioactive polymer has a refractive index of 1.4 to 1.6 or 1.45 to 1.55. B25. The method of any one of paragraphs B1-B24, further comprising hydrating the bioactive polymer. B26. The method according to paragraph B25, wherein the equilibrium water content of the hydrated bioactive polymer is 10-50% or 15-40%. B27. The method according to any one of paragraphs B1 to B26, carried out inside a mould. B28. The method of paragraph B27, comprising heating the mould to at least 50, 60, 70, 80, or 100°C. B29. The method of B27 or B28, wherein the mold is shaped to make an ophthalmic lens. B30. The method of paragraph B29, wherein the ophthalmic lens is an intraocular lens or a contact lens. B31. The method of any one of paragraphs B1-B30, wherein the bioactive agent comprises a protein, a protein fragment, a polypeptide of at least 50 amino acids, a peptide of 2-49 amino acids, a proteoglycan, a polysaccharide, an antimicrobial agent, and / or a therapeutic agent. B32. The method of paragraph B31, wherein the bioactive agent comprises an extracellular matrix protein, or a sequence of at least 5, 10, 25, 50, or 100 amino acids of an extracellular matrix protein. B33. The method of paragraph B32, wherein the extracellular matrix protein is collagen, elastin, keratin, vimentin, fibronectin, or laminin. B34. The method of any one of paragraphs B1-B33, wherein the bioactive polymer is foldable without substantially breaking, tearing, or shearing the matrix of the bioactive polymer. B35. The method of any one of paragraphs B1-B34, wherein conjugating comprises conjugating two or more copies of the first alkenyl moiety to the bioactive agent such that the bioactive monomer functions as a cross-linking monomer in a copolymerization reaction. B36. The method of any one of paragraphs B1-B35, wherein the bioactive monomer has a molecular weight that is at least 10, 50, 100, 500, or 1000 times that of at least one of the one or more other monomers. B37. A bioactive polymer produced by the method of any one of paragraphs B1-B36. B38.Ophthalmic lenses containing a bioactive polymer of heading B37.
[0030] C1. A bioactive monomer component comprising a bioactive agent; and one or more other monomeric components each of which does not contain a bioactive agent. 1. A bioactive polymer comprising: The bioactive polymer comprises a backbone that covalently bonds the bioactive monomeric component to each of one or more other monomeric components, each unit of the bioactive monomeric component donating at least two carbon atoms to the backbone, and each unit of each monomeric component of the one or more other monomeric components donating exactly two carbon atoms to the backbone. Bioactive polymers. C2. A bioactive polymer according to paragraph C1, wherein units of a bioactive monomeric component are interspersed along the backbone with units of one or more other monomeric components. C3. A bioactive polymer according to C1 or C2, wherein one or more other monomeric components form the majority of the bioactive copolymer. C4. The bioactive polymer of paragraph C3, wherein a majority of the bioactive polymer is at least 80%, 90%, 95%, or 98% of the bioactive polymer by mass or number of units. C5. The bioactive polymer of any one of paragraphs C1-C4, wherein the bioactive polymer comprises an acrylic polymer. C6. A bioactive polymer according to paragraph C1, wherein the one or more other monomers include an ultraviolet light blocking monomer, a crosslinking monomer, and / or a blue light blocking monomer. EXAMPLES
[0031] The following examples illustrate selected aspects of the disclosure and are not intended to limit or define the entire scope of the invention.
[0032] Example 1 Vinyl functionalization of proteins This example describes an exemplary method for vinyl functionalization of proteins. The free amines of lysine residues are reacted with vinyl groups to make vinyl-proteins (VPs) (i.e., vinyl collagen in Table 1, and vinyl gelatin, vinyl fibronectin, vinyl laminin, vinyl heparin, and vinyl hyaluronic acid in Table 2). The carboxyl groups of methacrylic acid are activated using 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide (EDC) and N-hydroxysuccinimide (NHS) in MES buffer. This mixture is added to 3.75 mg / mL of protein in 0.02 N acetic acid to form the final product. The product is dialyzed and lyophilized. Collagen type I was used as a representative bioactive protein for the polymers tested in Table 1.
[0033] Example 2 Preparation of the polymer This example describes an exemplary method for preparing bioactive polymers using the vinyl-protein of Example 1. Various polymer formulations and the results obtained with them are shown in Table 1. Various copolymers are prepared by mixing the following components under reduced pressure: (1) comonomers (e.g., VP, HEA, and MMA, or VP, HEMA, and LM), (2) crosslinker (e.g., EGDM), and (3) polymerizable UV-blocking agents. Vinyl benzotriazole or vinyl benzophenone is utilized as the UV-blocking agent at a total concentration of 0.1-5.0% by weight. A blue-light blocking chromophore may also be added at a concentration of 0.01% by weight. To initiate the polymerization, a free radical initiator (e.g., AIBN) is used at a concentration of 0.05-1.0% by weight. The monomer solution is mixed in a glass flask with a magnetic stir bar for 30 minutes. If the solution becomes cloudy, a small amount of formic acid may be added. The solution is then filtered through a 0.2 micron filter and poured into a plate-shaped mold made of two glass plates separated by a plastic gasket and secured with spring clips. The mold is then placed in a water bath at 60°C for 4 hours and then at 70°C for 6 hours. Table 1 shows the compositions of various bioactive polymers and vinyl collagen, along with their respective refractive indices and equilibrium water contents. Table 2 shows the composition of various bioactive polymers where the bioactive agent is either gelatin, fibronectin, laminin, heparin, and hyaluronic acid. Polymers 1 and 2 in Table 2 showed excellent results.
[0034] [Table 1] RI: Refractive Index EWC: Equilibrium water content 0.3 wt % MEB was used in all copolymer compositions. MEB: 2-(2'-methacryloxy-5'methylphenyl)benzotriazole
[0035] [Table 2] RI: Refractive Index EWC: Equilibrium water content MEB: 4-Methacryloxy-2-hydroxybenzophenone
[0036] The post-cure procedure is carried out as follows: 24 hours in a gravity oven at 100°C, followed by another 24 hours in a vacuum oven at 120°C. A transparent polymer sheet is obtained. Disks with a diameter of 1 cm and a thickness of 2 mm are cut from the sheet and allowed to hydrate. The equilibrium moisture content (EWC) is calculated from the hydrated and dry masses.
[0037] Example 3 Molding method This example describes a molding method. The monomer mixture is heated to 80° C. for approximately 30 minutes or until the viscosity is 1000 cps. The monomer mixture is then quenched in an ice bath. The cooled monomer solution is poured into an intraocular lens (IOL) mold and the mold is placed in a programmable oven with the following cycle: 1. 4 hours at 60℃ 2. 8 hours at 80℃ 3. 100℃ for 4 hours 4. In vacuum, 120℃ for 4 hours The IOL is removed from the mold and stored in a glass vial for future testing.
[0038] Although the present invention has been described through the above examples and features, those skilled in the art will appreciate that numerous modifications, combinations, and variations of the examples and features may be made without departing from the inventive concept disclosed herein. Furthermore, the present invention should not be considered limited to the specific objects or embodiments described herein, but rather should be considered applicable to achieve a wide variety of objects beyond those described herein. This disclosure describes several examples of the present technology, of which only a portion of the possible embodiments are shown. However, other aspects may be embodied in many different forms, and should not be construed as being limited to the examples described herein, even if the combination is not explicitly exemplified. Rather, these examples are provided so that the disclosure will be thorough and complete, and will fully convey the scope of possible embodiments to those skilled in the art.
Claims
1. 1. A method for producing a bioactive polymer, comprising: conjugating a bioactive agent to the moiety to form a bioactive monomer; and conducting a copolymerization reaction using as reactants the bioactive monomer and one or more other monomers each not containing the bioactive agent, wherein the moiety of the bioactive monomer reacts directly with at least one of the other monomers in the copolymerization reaction. The method includes:
2. The method of claim 1 , which produces an acrylic polymer or a silicone polymer.
3. The method of claim 1, wherein the bioactive agent comprises a protein, a protein fragment, a polypeptide of at least 50 amino acids, a peptide of 2-49 amino acids, a proteoglycan, a polysaccharide, an antimicrobial agent, and / or a therapeutic agent.
4. 2. The method of claim 1, wherein the bioactive agent comprises an extracellular matrix protein or a sequence of at least 5, 10, 25, 50, or 100 amino acids of the extracellular matrix protein.
5. The method of claim 4, wherein the extracellular matrix protein is collagen, elastin, keratin, vimentin, fibronectin, or laminin.
6. The method of claim 1 , wherein at least one of the one or more other monomers comprises a methacrylate compound, a methyl methacrylate compound, a hydroxyethyl acrylate compound, or a hydroxyethyl methacrylate compound.
7. The method of claim 1 , wherein the one or more other monomers include a hydrophilic monomer and a hydrophobic monomer.
8. The method of claim 7 , wherein the hydrophilic monomer has a hydroxyalkyl group attached directly to the oxygen atom of the ester functional group.
9. The method of claim 7 , wherein the hydrophobic monomer has an alkyl group attached directly to the oxygen atom of the ester functional group.
10. 1. A method for producing a bioactive polymer, comprising: conjugating a bioactive agent to the first alkenyl moiety to form a bioactive monomer; and conducting an alkenyl-based copolymerization reaction using as reactants at least said bioactive monomer and one or more other monomers, each of which contains an alkenyl moiety and does not contain said bioactive agent, to produce said bioactive polymer; Methods including:
11. 11. The method of claim 10, wherein the bioactive agent is selected from the group consisting of at least one of a protein, a protein fragment, a peptide, a polysaccharide, a polypeptide of at least 50 amino acids, a proteoglycan, an extracellular matrix protein, an antimicrobial agent, and a therapeutic agent.
12. The method of claim 10 , wherein at least one of the one or more other monomers is an acrylic compound.
13. 13. The method of claim 12, wherein the acrylic compounds are independently acrylic acid or an α / β substituted acrylic acid, an acrylic acid ester or an α / β substituted acrylic acid ester, or an acrylamide or an α / β substituted acrylamide.
14. The method of claim 10 , wherein at least one of the one or more other monomers comprises a methacrylate compound, a methyl methacrylate compound, a hydroxyethyl acrylate compound, or a hydroxyethyl methacrylate compound.
15. The method of claim 10 , wherein the one or more other monomers include a hydrophilic monomer and a hydrophobic monomer.
16. The method of claim 15 , wherein the hydrophilic monomer has a hydroxyalkyl group attached directly to the oxygen atom of the ester functional group.
17. The method of claim 15 , wherein the hydrophobic monomer has an alkyl group attached directly to the oxygen atom of the ester functional group.
18. The method of claim 10, wherein the bioactive polymer has a refractive index of 1.4 to 1.6 or 1.45 to 1.
55.
19. The method of claim 10, further comprising hydrating the bioactive polymer, wherein the equilibrium water content of the hydrated bioactive polymer is 10-50% or 15-40%.
20. A bioactive polymer produced by the method of claim 10.
